- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03336788
Virtual Reality Combined With rTMS for the Treatment of Depression : a Randomized Clinical Trial. (TMS VR)
Depression is a mood disorder affecting an individual in its entirety, altering its emotional and intellectual functioning . The major form of depression is the most common psychiatric disorder in Western countries. It is considered to be the most expensive psychiatric neurological disease in Europe and is currently treated by different methods.
However, almost a third of depressed patients shows no clinical improvement. Advances in neuroscience and understanding of neuromodulation have enabled the emergence of new treatments such as the repetitive transcranial magnetic stimulation (rTMS) . It consists of modulating the neuronal activity of a targeted brain region through a magnetic field applied by a coil. Even though this form of treatment has proven to be effective, it appears that more than half of depressed patients exhibited little to no response to it.
As brain regions targeted by TMS may also be stimulated beforehand by sensory afferent signals, it was hypothesized that optimizing the effects of TMS with virtual reality is possible through the activation of these brain regions with sensory stimuli holding emotional valence (images, sounds) while using TMS concomitantly. Based on this new research premise, the investigators propose, in the context of an open and controlled clinical trial, to use a new media entitled virtual reality for displaying interactive virtual environments with positive emotional valence ( field of flowers, green valley) to a group of depressed patients undergoing TMS at the same time.
The study will include 66 depressed patients randomly assigned into two groups : TMS and Virtual Reality Versus TMS alone. Any differences in therapeutic efficacy between the two groups will be measured by questionnaires and brain functional imagery. This innovative and therapeutic approach will allow us to better understand the appropriate processes for modulating the neuronal activity in specific brain areas for treatment purposes.
Study Overview
Status
Conditions
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Raphaëlle RICHIERI, PH
- Phone Number: +33 491435551
- Email: raphaellemarie.richieri@ap-hm.fr
Study Locations
-
-
-
Marseille, France, 13354
- Recruiting
- Assistance Publique Hopitaux de Marseille
-
Contact:
- Raphaëlle RICHIERI, PH
- Phone Number: +33 491435551
- Email: raphaellemarie.richieri@ap-hm.fr
-
Principal Investigator:
- Raphaëlle RICHIERI, PH
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Criteria of resistant depression
- Age from 18 to 65 years old included.
- Primary diagnosis of major depression in subjects according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria.
- Informed consent and signed to participate in the study
Exclusion Criteria:
- Pregnant woman, parturient and nursing mothers.
- Absence of DSM-5 criteria for depression in subjects.
- Refusal to participate in the study.
- Modification of drug treatment in the month preceding inclusion.
- History of neurological pathology, head trauma or mental retardation.
- Presence of an addictive comorbidity.
- Presence of a major organic pathological.
- Presence of a contra-indication to virtual reality
- Presence of intracerebral ferro-metallic material, cochlear implant, pacemaker
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: TMS
|
20 sessions navigated with Conventional Transcranial Magnetic Stimulation
|
Active Comparator: TMS with virtual reali
|
20 sessions navigated with Conventional Transcranial Magnetic Stimulation
20 sessions navigated with virtual reality
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of the depression score in Montgomery-asberg Depression Rating Scale (MADRS).
Time Frame: 36 months
|
a heteroevaluation scale of depressive semiology in 10 items.
A decrease of at least 50% in initial score at the Montgomery-asberg Depression Rating Scale.
|
36 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of The State Trait Anxiety Inventory Self-Questionnaire
Time Frame: 36 months
|
40 items with, for each, 4 modalities of response, corresponding to degrees of intensity or frequency of the habitual or general emotional state of the patient.
The calculated score varies between 20 and 80, a high score indicating the presence of anxiety.
Anxiety will be assessed before the program begins and at the end of the program.
|
36 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Raphaëlle RICHIERI, PH, Assistance Publique Hopitaux de Marseille
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2016-21
- 2016-A01115-46 (Registry Identifier: ID RCB)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on the Treatment of Depression
-
SPS srlNot yet recruitingTreatment of Degenerative Diseases of the SpineItaly
-
Solta MedicalCompletedTreatment of Adipose Tissue in the ThighsUnited States, Canada
-
Assistance Publique Hopitaux De MarseilleCompletedImprove the Understanding of the Diagnosis the Treatment and the Prognosis by One Member of the FamilyFrance
-
Centre Hospitalier de TroyesInstitut National de la Santé Et de la Recherche Médicale, FranceNot yet recruitingOSTEOPATHY IN THE TREATMENT OF IBS SYMPTOMS IN ADULTS
-
U.S. Army Medical Research and Development CommandCompletedTreatment Against the Lethal Effects of Nerve Agent IntoxicationUnited States
-
University Hospital of PatrasNot yet recruitingStudy Focuses on the Use of Covered Stents (Stent Grafts) for the Treatment of Dysfunctional Vascular Access of Hemodialysis Patients
-
Assiut UniversityUnknownTreatment of Terrible Triade Injury of the Elbow JointEgypt
-
Guangdong Provincial People's HospitalUnknownTMS Protocols in the Treatment of PDChina
-
RWTH Aachen UniversityUnknownRecruitment | Bronchoscopy | Electric Impedance Tomography | Change in Lung Impedance Due to Ventilation | Improvement the Treatment of the PatientGermany
-
Second Affiliated Hospital, School of Medicine,...First Affiliated Hospital of Jinan University; First Affiliated Hospital of... and other collaboratorsRecruitingEvaluate the Efficacy of Cyclical Topical Wound Oxygen Therapy in the Treatment of Chronic WoundsChina
Clinical Trials on Transcranial Magnetic Stimulation (TMS - ) MagPro®
-
Assistance Publique Hopitaux De MarseilleCompleted
-
Universidad Nacional Autonoma de MexicoUnknownMajor DepressionMexico
-
Medical University of South CarolinaRecruitingStroke Sequelae | Motivation | Apathy | Stroke (CVA) or TIA | Stroke/Brain Attack | AbuliaUnited States
-
The Mind Research NetworkUniversity of New MexicoRecruitingTranscranial Magnetic Stimulation | Traumatic Brain Injury | Magnetic Resonance Imaging | Post-Concussion Syndrome | Neuropsychological TestsUnited States
-
NeuroneticsUnknownMajor Depressive DisorderUnited States
-
Emory UniversityNational Institute of Mental Health (NIMH)Recruiting
-
Centre Hospitalier St AnneNot yet recruitingTreatment Resistant Schizophrenia
-
University of California, San DiegoNational Institutes of Health (NIH)RecruitingMajor Depressive DisorderUnited States, Australia
-
Northwestern UniversityCompletedHealthyUnited States
-
University of FloridaActive, not recruiting